Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.42 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7251427 | 0.80 | LMNA (0.59) | PTGS2PPARGPPARAALOX5 | |
| SCHEMBL27621298 | 0.79 | PTGS2 (0.56) | PTGS2CDK1PPARAGPR84CYP3A4 | |
| SCHEMBL8432218 | 0.79 | PTGS2 (0.56) | PTGS2CDK1PPARAGPR84CYP3A4 | |
| SCHEMBL27328483 | 0.78 | ALOX5 (0.50) | PTGS2PPARGPPARAGPR84CYP3A4 | |
| SCHEMBL10119938 | 0.78 | PTGS2 (0.52) | PTGS2CA1CA2 | |
| SCHEMBL31455929 | 0.76 | PPARG (0.59) | CDK1PPARGPPARACYP3A4 | |
| SCHEMBL31442610 | 0.76 | PPARG (0.59) | CDK1PPARGPPARACYP3A4 | |
| SCHEMBL10773005 | 0.75 | PTGS2 (0.59) | PTGS2PPARGPPARAALOX5 | |
| SCHEMBL10772012 | 0.75 | PTGS2 (0.59) | PTGS2PPARGPPARAALOX5 | |
| SCHEMBL10774727 | 0.75 | PTGS2 (0.59) | PTGS2PPARGPPARAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-8110679-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-7767810-B2 | Macrocyclic modules comprising linked cyclic synthon units for use in the formation of selectively permeable membranes | COVALENT PARTNERS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7595368-B2 | Nanofilm compositions with polymeric components | COVALENT PARTNERS, LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090114596-A1 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS LLC | 2009-05-07 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-7432371-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS, LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060128680-A1 | Macrocyclic module compositions | KRIESEL JOSH | 2006-06-15 | — | — | US | disclosed |
| EP-1480635-A4 | MACROCYCLIC MODULE COMPOSITIONS | COVALENT PARTNERS LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005030711-A2 | BRIDGED MACROCYCLIC MODULE COMPOSITIONS | COVALENT PARTNERS LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005018013-A2 | NANOFILM COMPOSITIONS WITH POLYMERIC COMPONENTS | COVALENT PARTNERS, LLC (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040260085-A1 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC | 2004-12-23 | — | — | US | disclosed |
| EP-1481268-A2 | NANOFILM AND MEMBRANE COMPOSITIONS | Covalent Partners, LLC (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1480635-A2 | MACROCYCLIC MODULE COMPOSITIONS | Covalent Partners, LLC (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040106741-A1 | Nanofilm compositions with polymeric components | COVALENT PARTNERS LLC | 2004-06-03 | — | — | US | disclosed |
| US-20030199688-A1 | Macrocyclic module compositions | COVALENT PARTNERS, LLC | 2003-10-23 | — | — | US | disclosed |
| WO-2003067286-A2 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS, LLC (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066646-A2 | MACROCYCLIC MODULE COMPOSITIONS | COVALENT PARTNERS, LLC (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199688-A1 | Macrocyclic module compositions | CYCS, IMMT, INTS9 | PTGS2 1742/4885CDK1 91/4885PPARG 4265/4885 |
| US-20060128680-A1 | Macrocyclic module compositions | CYCS, IMMT, INTS9 | PTGS2 1742/4885CDK1 91/4885PPARG 4265/4885 |
| US-20040260085-A1 | Nanofilm and membrane compositions | CLPTM1, APMAP, PHOSPHO1 | PTGS2 4640/4885CDK1 4120/4885PPARG 4678/4885 |
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | PTGS2 2818/4885CDK1 52/4885PPARG 4490/4885 |
| US-20080290034-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | PTGS2 3056/4885CDK1 48/4885PPARG 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.